Minimum effective dose-finding study of BF2.649, in patients with moderate to severe Obstructive Sleep Apnea, experiencing Excessive Daytime Sleepiness (EDS) despite regular use of nCPAP, and patients having refused this therapy. Randomized, double blind study with BF2.649 (5-, 10-, 20-, 40- mg/d), or placebo.

Trial Profile

Minimum effective dose-finding study of BF2.649, in patients with moderate to severe Obstructive Sleep Apnea, experiencing Excessive Daytime Sleepiness (EDS) despite regular use of nCPAP, and patients having refused this therapy. Randomized, double blind study with BF2.649 (5-, 10-, 20-, 40- mg/d), or placebo.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2014

At a glance

  • Drugs Pitolisant (Primary)
  • Indications Sleep apnoea syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jun 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01620554).
    • 13 Jun 2012 Lead trial investigator identified as reported by ClinicalTrials.gov.
    • 13 Jun 2012 Actual patient number 110 added as reported by ClincialTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top